You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 5,192,659

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,192,659

Title:	Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
Abstract:	The present invention provides a method for detection of at least one allele of a genetic locus and can be used to provide direct determination of the haplotype. The method comprises amplifying genomic DNA with a primer pair that spans an intron sequence and defines a DNA sequence in genetic linkage with an allele to be detected. The primer-defined DNA sequence contains a sufficient number of intron sequence nucleotides to characterize the allele. Genomic DNA is amplified to produce an amplified DNA sequence characteristic of the allele. The amplified DNA sequence is analyzed to detect the presence of a genetic variation in the amplified DNA sequence such as a change in the length of the sequence, gain or loss of a restriction site or substitution of a nucleotide. The variation is characteristic of the allele to be detected and can be used to detect remote alleles. Kits comprising one or more of the reagents used in the method are also described.
Inventor(s):	Simons; Malcolm J. (Fryerstown, AU)
Assignee:	GeneType AG (Zug, CH)
Application Number:	07/551,239
Patent Claims:	1. A method for detection of at least one coding region allele of an HLA locus comprising amplifying genomic DNA with a primer pair that spans a non-coding region sequence selected from the group consisting of untranslated sequences between exons, 5' and 3' untranslated regions associated with a genetic locus, and spacing sequences between genetic loci, said primer pair defining a DNA sequence, said DNA sequence being in genetic linkage with said HLA locus and containing a sufficient number of said non-coding region sequence nucleotides to produce an amplified DNA sequence characteristic of said allele. 2. The method of claim 1 wherein said amplified DNA sequence includes at least about 300 nucleotides corresponding to intron sequences. 3. The method of claim 1 wherein said intron sequence is adjacent to an exon encoding said allele. 4. The method of claim 1 wherein said amplified DNA sequence is characteristic of at least one nonadjacent allele. 5. The method of claim 1 wherein said amplified DNA sequence is characteristic of at least one adjacent allele and at least one nonadjacent allele. 6. The method of claim 5 wherein said amplified DNA sequence includes at least about 1,000 nucleotides corresponding to non-coding region sequences. 7. A method for detection of at least one allele of an HLA locus comprising: A. amplifying genomic DNA with a primer pair that spans a non-coding region sequence selected from the group consisting of untranslated sequences between exons, 5' and 3' untranslated regions associated with a genetic locus, and spacing sequences between genetic loci, said primer pair defining a DNA sequence, said DNA sequence being in genetic linkage with said allele and containing a sufficient number of said non-coding region sequence nucleotides to produce an amplified DNA sequence characteristic of said allele; and B. analyzing said amplified DNA sequence to detect the presence of a genetic variation in said amplified sequence. 8. The method of claim 7 wherein said variation in said amplified DNA sequence is a variation in the length of the primer-defined amplified DNA sequence. 9. The method of claim 7 wherein said variation in said amplified DNA sequence is a change in the presence of at least one restriction site in the primer-defined amplified DNA sequence. 10. The method of claim 7 wherein said variation in said amplified DNA sequence is a change in the location of at least one restriction site in the primer-defined amplified DNA sequence. 11. The method of claim 7 wherein said variation in said amplified DNA sequence is a substitution of at least one nucleotide in the primer-defined amplified DNA sequence.

Details for Patent 5,192,659

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986	⤷ Try a Trial	2010-03-09
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132		⤷ Try a Trial	2010-03-09
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132		⤷ Try a Trial	2010-03-09
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.